Supplier Antibody Serology Research of Virus within the Emergency Room (PASSOVER) Research: Particular Inhabitants COVID-19 Seroprevalence
Introduction: Restricted information on the seroprevalence of extreme acute respiratory syndrome coronavirus 2 (SARS-CoV-2) amongst healthcare employees (HCW) are publicly accessible. On this research we sought to find out the seroprevalence of SARS-CoV-2 in a inhabitants of HCWs in a pediatric emergency division (ED).
Strategies: We carried out this observational cohort research from April 14-Might 13, 2020 in a pediatric ED in Orange County, CA. Asymptomatic HCW ≥18 years of age have been included within the research. Blood samples have been obtained by fingerstick at first of every shift. The inter-sampling interval was ≤96 hours. The first consequence was optimistic seroprevalence of SARS-CoV-2 as decided with an antibody quick detection equipment (Colloidal Gold, Superbio, Timisoara, Romania) for the SARS-CoV-2 immunoglobulin M/immunoglobulin G (IgM/IgG) antibody.
Outcomes: A complete of 143 HCWs participated within the research. Total SARS-CoV-2 seroprevalence was 10.5% (n = 15). Optimistic seroprevalence was labeled as IgG solely (4.9%), IgM+IgG (3.5%), or IgM solely (2.1%). SARS-CoV-2 was detected by reverse transcription polymerase chain response RT-PCR in 0.7% of the general research inhabitants (n = 1). Samples obtained on Day 1 indicated seropositivity in 4.2% of the research inhabitants (n = 6). Subsequent seroconversion occurred in 6.3% of contributors (n = 9). The speed of seroconversion was linear with a fee of roughly one new case each two days, beginning at Day 9 of the research.
Conclusion: We noticed a linear fee of seroconversion to SARS-CoV-2-positive standing amongst asymptomatic HCWs who underwent each day symptom surveys and temperature screens in an atmosphere with common supply management. Fast antibody testing could also be helpful for screening for SARS-CoV-2 seropositivity in high-risk populations, equivalent to HCWs within the ED.
Cluster Percolation Causes Shear Thinning Habits in Concentrated Options of Monoclonal Antibodies
Excessive-concentration (>100 g/L) options of monoclonal antibodies (mAbs) are usually characterised by anomalously massive answer viscosity and shear thinning habits for pressure charges ≥103 s-1. Right here, the hyperlink between protein-protein interactions (PPIs) and the rheology of concentrated options of COE-03 and COE-19 mAbs is studied via static and dynamic gentle scattering and microfluidic rheometry. By evaluating the experimental information with predictions primarily based on the Baxter sticky hard-sphere mannequin, we surprisingly discover a connection between the noticed shear thinning and the expected percolation threshold.
The longest shear rest time of mAbs was a lot bigger than that of mannequin sticky arduous spheres inside the similar area of the part diagram, which is attributed to the anisotropy of the mAb PPIs. Our outcomes recommend that not solely the power but in addition the patchiness of short-range engaging PPIs needs to be explicitly accounted for by theoretical approaches aimed toward predicting the shear rate-dependent viscosity of dense mAb options.
Priming of pancreatic most cancers cells with bispecific antibody armed activated T cells sensitizes tumors for enhanced chemoresponsiveness
On this research, we investigated the power of bispecific antibody armed activated T cells to focus on drug resistant pancreatic most cancers cells and whether or not or not “priming” these resistant most cancers cells with bispecific antibody armed activated T cells may improve subsequent responsiveness to chemotherapeutic medication. Chemotherapeutic responses for pancreatic most cancers are both restricted or the tumors develop resistance to chemotherapy regimens. The impetus for this research was the outstanding scientific response seen in our earlier part I/II scientific trial: a pancreatic most cancers affected person with drug resistant tumors who confirmed development of illness following three infusions of anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (EGFR BATs) was restarted on the preliminary low dose of <i>5-fluorouracil</i> confirmed full response, suggesting that BATs infusions could have sensitized affected person’s tumor for chemoresponsiveness.
Within the present research, we examined the speculation that BATs can sensitize tumors for chemoresponsiveness. Gemcitabine or cisplatin-resistant MiaPaCa-2 and L3.6 cell traces have been successfully focused by EGFR BATs. Priming of drug delicate or resistant cells with EGFR BATs adopted by retargeting with decrease concentrations of 50% inhibitory focus of gemcitabine or cisplatin confirmed enhanced cytotoxicity. Gemcitabine or cisplatin-resistant cell traces present an elevated proportion of CD44 most cancers stem-like cells in addition to an elevated variety of ABC transporter ABCG2 optimistic cells in comparison with the parental cell traces. These information recommend that bispecific antibody armed activated T cells can goal and kill chemo-resistant tumor cells and in addition markedly increase subsequent chemotherapeutic responsiveness, presumably by modulating the expression of ABC transporters.
Prediction and mitigation of mutation threats to COVID-19 vaccines and antibody therapies
Antibody therapeutics and vaccines are amongst our final resort to finish the raging COVID-19 pandemic. They, nonetheless, are susceptible to over 5000 mutations on the spike (S) protein uncovered by a Mutation Tracker primarily based on over 200 000 genome isolates. It’s crucial to grasp how mutations will influence vaccines and antibodies in improvement. On this work, we first research the mechanism, frequency, and ratio of mutations on the S protein which is the frequent goal of most COVID-19 vaccines and antibody therapies. Moreover, we construct a library of 56 antibody buildings and analyze their 2D and 3D traits. Furthermore, we predict the mutation-induced binding free vitality (BFE) modifications for the complexes of S protein and antibodies or ACE2. By integrating genetics, biophysics, deep studying, and algebraic topology, we reveal that many of the 462 mutations on the receptor-binding area (RBD) will weaken the binding of S protein and antibodies and disrupt the efficacy and reliability of antibody therapies and vaccines.
A listing of 31 antibody disrupting mutants is recognized, whereas many different disruptive mutations are detailed as effectively. We additionally unveil that about 65% of the prevailing RBD mutations, together with these variants not too long ago present in the UK (UK) and South Africa, will strengthen the binding between the S protein and human angiotensin-converting enzyme 2 (ACE2), leading to extra infectious COVID-19 variants. We uncover the disparity between the excessive values of RBD mutation-induced BFE strengthening and weakening of the bindings with antibodies and angiotensin-converting enzyme 2 (ACE2), suggesting that SARS-CoV-2 is at a complicated stage of evolution for human an infection, whereas the human immune system is ready to produce optimized antibodies. This discovery, sadly, implies the vulnerability of present vaccines and antibody medication to new mutations. Our predictions have been validated by comparability with greater than 1400 deep mutations on the S protein RBD. Our outcomes present the pressing have to develop new mutation-resistant vaccines and antibodies and to organize for seasonal vaccinations.
Anti-Mouse LIF Antibody |
|||
103-M263 | ReliaTech | 100 µg | EUR 399 |
Description: Based on its helical structure, LIF (Leukemia Inhibitory Factor) is considered a member of the Interleukin-6 family of cytokines. Functionally, it has been implicated in a many physiological processes including development, hematopoiesis, bone metabolism, and inflammation. Some cell types known to express LIF include activated T cells, monocytes, astrocytes, osteoblasts, keratinocytes, regenerating skeletal muscle, mast cells, and fibroblasts. |
Anti-Mouse LIF Antibody |
|||
103-PA05S | ReliaTech | 100 µg | EUR 126 |
Description: Leukemia Inhibitory Factor also called LIF is a lymphoid factor that promotes long-term maintenance of embryonic stem cells by suppressing spontaneous differentiation. Leukemia Inhibitory Factor has several functions such as cholinergic neuron differentiation, control of stem cell pluripotency, bone & fat metabolism, mitogenesis of factor dependent cell lines & promotion of megakaryocyte production in vivo. Human and mouse LIF exhibit a 78% identity in its amino acid sequence. Human LIF is as active on human cells as is it is on mouse cells, though mouse LIF is about 1000 fold less active on human cells, than human LIF. |
Rabbit Anti-Mouse LIF |
|||
103-PA05 | Angio Proteomie | 100ug | EUR 240 |
Mouse LIF Protein |
|||
E40MOP1672 | EnoGene | 20ug | EUR 495 |
Mouse LIF Protein |
|||
E40MOP2026 | EnoGene | 20ug | EUR 495 |
Mouse LIF Protein |
|||
E40MOP2028 | EnoGene | 20ug | EUR 495 |
Recombinant Mouse LIF |
|||
Z200195 | ABM | 10 µg | EUR 85 |
Description: LIF is a multifunctional secreted glycoprotein that exists in both soluble and matrix-bound forms. It displays biologic activities ranging from the differentiation of myeloid leukemic cells into macrophage lineage to effects on bone metabolism, inflammation, neural development, embryogenesis, and the maintenance of implantation. It is now clear that LIF is related in both structure and mechanism of action to the interleukin IL-6 family of cytokines, which also includes IL-11, ciliary neurotrophic factor, oncostatin M, and cardiotrophin 1. The actions of these cytokines are mediated through specific cell-surface receptors that consist of a unique chain and the shared signal transducing subunit gp130. |
Recombinant Mouse LIF |
|||
Z200197 | ABM | 100 µg | EUR 385 |
Description: LIF is a multifunctional secreted glycoprotein that exists in both soluble and matrix-bound forms. It displays biologic activities ranging from the differentiation of myeloid leukemic cells into macrophage lineage to effects on bone metabolism, inflammation, neural development, embryogenesis, and the maintenance of implantation. It is now clear that LIF is related in both structure and mechanism of action to the interleukin IL-6 family of cytokines, which also includes IL-11, ciliary neurotrophic factor, oncostatin M, and cardiotrophin 1. The actions of these cytokines are mediated through specific cell-surface receptors that consist of a unique chain and the shared signal transducing subunit gp130. |
Recombinant Mouse LIF |
|||
Z200199 | ABM | 1.0 mg | EUR 1200 |
Description: LIF is a multifunctional secreted glycoprotein that exists in both soluble and matrix-bound forms. It displays biologic activities ranging from the differentiation of myeloid leukemic cells into macrophage lineage to effects on bone metabolism, inflammation, neural development, embryogenesis, and the maintenance of implantation (2). It is now clear that LIF is related in both structure and mechanism of action to the interleukin IL-6 family of cytokines, which also includes IL-11, ciliary neurotrophic factor, oncostatin M, and cardiotrophin 1 (2). The actions of these cytokines are mediated through specific cell-surface receptors that consist of a unique chain and the shared signal transducing subunit gp130. |
Recombinant Mouse LIF |
|||
Z200485 | ABM | 100 µg | EUR 1500 |
Description: LIF is a multifunctional secreted glycoprotein that exists in both soluble and matrix-bound forms. It displays biologic activities ranging from the differentiation of myeloid leukemic cells into macrophage lineage to effects on bone metabolism, inflammation, neural development, embryogenesis, and the maintenance of implantation (2). It is now clear that LIF is related in both structure and mechanism of action to the interleukin IL-6 family of cytokines, which also includes IL-11, ciliary neurotrophic factor, oncostatin M, and cardiotrophin 1 (2). The actions of these cytokines are mediated through specific cell-surface receptors that consist of a unique chain and the shared signal transducing subunit gp130. |
anti- LIF antibody |
|||
FNab09804 | FN Test | 100µg | EUR 658.5 |
Description: Antibody raised against LIF |
anti- LIF antibody |
|||
LSMab09804 | Lifescience Market | 100 ug | EUR 463.2 |
Mouse LIF ELISA Kit |
|||
E28L0650 | EnoGene | 96T | EUR 666.67 |
Mouse LIF ELISA Kit |
|||
EK5250 | SAB | 96 tests | EUR 599 |
Mouse LIF ELISA Kit |
|||
EML0014 | Abclonal | 96Tests | EUR 625.2 |
Rat Monoclonal anti-mouse LIF |
|||
mAP-0122 | Angio Proteomie | 100ug | EUR 250 |
Sheep Polyclonal anti-mouse LIF |
|||
mAP-5260 | Angio Proteomie | 50ug | EUR 400 |
Mouse LIF shRNA Plasmid |
|||
20-abx971321 | Abbexa |
|
|
Mouse LIF Recombinant Protein |
|||
M30-007 | ReliaTech | 10 µg | EUR 99.75 |
Description: Leukemia Inhibitory Factor also called LIF is a lymphoid factor that promotes long-term maintenance of embryonic stem cells by suppressing spontaneous differentiation. Leukemia Inhibitory Factor has several functions such as cholinergic neuron differentiation, control of stem cell pluripotency, bone & fat metabolism, mitogenesis of factor dependent cell lines & promotion of megakaryocyte production in vivo. Human and mouse LIF exhibit a 78% identity in its amino acid sequence. Human LIF is as active on human cells as is it is on mouse cells, though mouse LIF is about 1000 fold less active on human cells, than human LIF. Recombinant mouse LIF produced in E. coli is a single, non-glycosylated, polypeptide chain containing 180 amino acids and having a molecular mass of 19.86 kDa. |
Mouse LIF Recombinant Protein |
|||
M30-008 | ReliaTech | 50 µg | EUR 246.75 |
Description: Leukemia Inhibitory Factor also called LIF is a lymphoid factor that promotes long-term maintenance of embryonic stem cells by suppressing spontaneous differentiation. Leukemia Inhibitory Factor has several functions such as cholinergic neuron differentiation, control of stem cell pluripotency, bone & fat metabolism, mitogenesis of factor dependent cell lines & promotion of megakaryocyte production in vivo. Human and mouse LIF exhibit a 78% identity in its amino acid sequence. Human LIF is as active on human cells as is it is on mouse cells, though mouse LIF is about 1000 fold less active on human cells, than human LIF. Recombinant mouse LIF produced in E. coli is a single, non-glycosylated, polypeptide chain containing 180 amino acids and having a molecular mass of 19.86 kDa. |
Recombinant Mouse LIF Protein |
|||
R01400-1 | BosterBio | 100ug/vial | EUR 352.8 |
Recombinant Mouse LIF Protein |
|||
PKSM041100-100ug | Elabscience Biotech | 100ug | EUR 739 |
Description: Mouse |
Recombinant Mouse LIF Protein |
|||
PKSM041100-20ug | Elabscience Biotech | 20ug | EUR 249 |
Description: Mouse |
Mouse LIF PicoKine ELISA Kit |
|||
EK0580 | BosterBio | 96 wells | EUR 510 |
Description: For quantitative detection of mouse LIF in cell culture supernates, serum and plasma (heparin, EDTA). |
Anti-Human LIF Antibody |
|||
101-M553 | ReliaTech | 100 µg | EUR 399 |
Description: Based on its helical structure, LIF (Leukemia Inhibitory Factor) is considered a member of the Interleukin-6 family of cytokines. Functionally, it has been implicated in a many physiological processes including development, hematopoiesis, bone metabolism, and inflammation. Some cell types known to express LIF include activated T cells, monocytes, astrocytes, osteoblasts, keratinocytes, regenerating skeletal muscle, mast cells, and fibroblasts. |
Anti-Human LIF Antibody |
|||
102-PA05S | ReliaTech | 100 µg | EUR 126 |
Description: Leukemia Inhibitory Factor also called LIF is a lymphoid factor that promotes long-term maintenance of embryonic stem cells by suppressing spontaneous differentiation. Leukemia Inhibitory Factor has several functions such as cholinergic neuron differentiation, control of stem cell pluripotency, bone & fat metabolism, mitogenesis of factor dependent cell lines & promotion of megakaryocyte production in vivo. Human and mouse LIF exhibit a 78% identity in its amino acid sequence. Human LIF is as active on human cells as is it is on mouse cells, though mouse LIF is about 1000 fold less active on human cells, than human LIF. |
LIF mouse monoclonal antibody, clone 4F7.2 |
|||
MO16101-100 | Origene Technologies GmbH | 100 µg | Ask for price |
LIF mouse monoclonal antibody, clone 2H2.2 |
|||
MO16102-100 | Origene Technologies GmbH | 100 µg | Ask for price |
Lif ORF Vector (Mouse) (pORF) |
|||
ORF049145 | ABM | 1.0 ug DNA | EUR 607.2 |
Lif ORF Vector (Mouse) (pORF) |
|||
ORF049146 | ABM | 1.0 ug DNA | EUR 607.2 |
Rabbit Anti-Human LIF |
|||
102-PA05 | Angio Proteomie | 100ug | EUR 240 |